Immunic (IMUX) Cash & Equivalents (2013 - 2026)

Immunic (IMUX) has 14 years of Cash & Equivalents data on file, last reported at $186.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 1204.53% year-over-year to $186.6 million; the trailing twelve-month figure through Mar 2026 stood at $186.6 million (up 1204.53% YoY), and the FY2025 full-year result was $15.5 million, down 56.59% from the prior year.
• Cash & Equivalents improved to $186.6 million in Q1 2026, from $15.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $186.6 million in Q1 2026 to a low of $14.3 million in Q1 2025.
• A 5-year average of $71.7 million and a median of $72.8 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 85.3% in 2025 and jumped 1204.53% in 2026, its largest moves.
• Tracing IMUX's Cash & Equivalents over 5 years: stood at $106.7 million in 2022, then plunged by 56.28% to $46.7 million in 2023, then decreased by 23.58% to $35.7 million in 2024, then sank by 56.59% to $15.5 million in 2025, then surged by 1105.19% to $186.6 million in 2026.
• Business Quant data shows IMUX's Cash & Equivalents at $186.6 million in Q1 2026, $15.5 million in Q4 2025, and $35.1 million in Q3 2025.